PriceTargets.com logo

Rein Therapeutics - RNTX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.00
  • Forecasted Upside: 488.24%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.36 As of 12/5/2025 05:00 PM ET
▼ -0.03 (-2.16%)

This chart shows the closing price for RNTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rein Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RNTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RNTX

Analyst Price Target is $8.00
▲ +488.24% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Rein Therapeutics in the last 3 months. The average price target is $8.00, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 488.24% upside from the last price of $1.36.

This chart shows the closing price for RNTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Rein Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/3/2025Loop CapitalSet Target$6.00
11/3/2025Brookline Capital ManagementUpgradeHold ➝ Buy
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/22/2025HC WainwrightInitiated CoverageBuy$10.00
9/22/2025HC WainwrightInitiated CoverageBuy$10.00
8/19/2025Brookline Capital ManagementDowngradeBuy ➝ Hold
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Rein Therapeutics logo
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Read More

Today's Range

Now: $1.36
Low: $1.34
High: $1.38

50 Day Range

MA: $1.38
Low: $1.15
High: $1.75

52 Week Range

Now: $1.36
Low: $1.04
High: $3.50

Volume

163,085 shs

Average Volume

228,852 shs

Market Capitalization

$35.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Rein Therapeutics?

The following Wall Street analysts have issued research reports on Rein Therapeutics in the last year: Brookline Capital Management, HC Wainwright, Loop Capital, and Weiss Ratings.
View the latest analyst ratings for RNTX.

What is the current price target for Rein Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Rein Therapeutics in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 488.2%. HC Wainwright has the highest price target set, predicting RNTX will reach $10.00 in the next twelve months. Loop Capital has the lowest price target set, forecasting a price of $6.00 for Rein Therapeutics in the next year.
View the latest price targets for RNTX.

What is the current consensus analyst rating for Rein Therapeutics?

Rein Therapeutics currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RNTX, but not buy more shares or sell existing shares.
View the latest ratings for RNTX.

What other companies compete with Rein Therapeutics?

Other companies that are similar to Rein Therapeutics include Coherus Oncology, Seres Therapeutics, Nuvectis Pharma, Cassava Sciences and Connect Biopharma. Learn More about companies similar to Rein Therapeutics.

How do I contact Rein Therapeutics' investor relations team?

Rein Therapeutics' physical mailing address is 12407 N. MOPAC EXPY., SUITE 250 #390, AUSTIN, TX, 78758. The company's listed phone number is (737) 802-1989 and its investor relations email address is [email protected]. The official website for Rein Therapeutics is aileronrx.com. Learn More about contacing Rein Therapeutics investor relations.